A recent double-blind, placebo-controlled randomized clinical trial involving 108 HIV patients with HIV-associated lipohypertrophy has demonstrated that semaglutide, a GLP-1 receptor agonist marketed as Ozempic and Wegovy, slows epigenetic aging in humans. Over a 32-week period, participants receiving semaglutide showed a reduction in biological age across multiple epigenetic methylation clocks and 11 organ and system aging measures compared to those on placebo. This phase 2b trial, which included 45 patients on semaglutide and 39 on placebo, provides evidence that semaglutide may reverse or delay biological aging processes beyond its known effects on weight loss. Researchers note that further studies comparing GLP-1 receptor agonists to equivalent weight loss without the drug are needed to isolate the specific anti-aging benefits of semaglutide.